Norwegian biotechTargovax has appointed its new chief business officer in the form of Michael Bogenstaetter, who joins following 25 years’ experience in the biotech and pharmaceutical industries.
Bogenstaetter previously served as an advisor of life sciences and health care at Interim Assignments, and before that he served as global head strategy, project management and operations drug discovery at Sanofi.
He has also held numerous roles for Novartis, MSD and Johnson and Johnson.
Øystein Soug, chief executive officer of Targovax, said: “Bogenstaetter’s extensive experience of business development and corporate strategy in the biotech and pharma industry will be indispensable to us.”